Hi! I am Andrii Buvailo, and this is my weekly newsletter, ‘Where Tech Meets Bio,’ where I talk about technologies, breakthroughs, and great companies moving the biopharma industry forward.
If you've received it, then you either subscribed or someone forwarded it to you. If the latter is the case, subscribe by pressing this button:
This week’s newsletter is brought to you by BiopharmaTrend.com.
The company created “The State of AI in the Biopharma Industry,” which is a unique resource for tech scouting, competitive intelligence, and strategizing about artificial intelligence (AI) for pharma and biotech.
Watch a brief report overview below (under 4 minutes of watch time) 👇
Now, let’s get back to today’s topics!
Weekly TECH+BIO highlights:
💰 VantAI strikes $674M deal with BMS on AI-driven molecular glues
🛑 Prominent AI-biotech Exscientia fires Co-founder and CEO Andrew Hopkins for inappropriate relationships with employees; Chief Scientific Officer Dave Hallett steps in as interim CEO.
💰 BioAge secures $170M in oversubscribed Series D financing for obesity and metabolic disease therapeutics, advancing Phase 2 trials of azelaprag with Lilly’s Zepbound.
The Growing Diversity of Antibody-Drug Conjugates in Cancer Therapy
Since the first antibody-drug conjugate (ADC) was approved in 2000, the ADC field has seen significant transformation. It has revolutionized treatment for advanced-stage cancers, including solid tumors.
I have recently come accross a solid review article where two scientists from Denmark, Dr. Virginia Metrangolo and Dr. Lars Engelholm delve into the rapid advancements and breakthroughs in ADCs.
These innovations in design and development make ADCs highly adaptable. They can be precisely tailored to match tumor biology, promising a new era of personalized cancer therapy.
According to authors, currently, 14 ADCs are available globally, with over 100 in clinical trials. This targeted approach is set to transform cancer treatment. Notably, 7 ADCs target solid tumors, expanding the range of treatable cancers. This also introduces new possibilities for combination therapies against the toughest cancer types.

Navigating Next Wave of Protein Design with Elise de Reus from Cradle
Cradle, a Dutch-Swiss biotech startup founded in 2021, is advancing the field of protein design by leveraging generative artificial intelligence (AI).
The company, with its headquarters in Delft, the Netherlands, and additional operations in Zurich, Switzerland, has developed a web-based software platform aimed at accelerating the R&D pipelines in biotechnology.
This platform enables scientists and experimentalists to design and engineer proteins more efficiently by breaking down traditional data roadblocks without the need for specialized knowledge in bioinformatics or machine learning.
In November 2023, Cradle raised $24 million in a Series A funding round, bringing its total funding to $33 million. The round was led by Index Ventures, with participation from Kindred Capital and notable angel investors such as Chris Gibson, co-founder and CEO of Recursion, and Tom Glocer, former CEO of Thomson Reuters.
The company plans to further expand its team and build out additional laboratory and engineering facilities in Amsterdam in 2024.
Since coming out of stealth mode in 2022, Cradle has onboarded several industry partners, including Johnson & Johnson Innovation, Novozymes, and Twist Bioscience, and is now working on over a dozen of R&D projects.
These projects span a wide range of protein modalities, such as enzymes, vaccines, peptides, and antibodies, aiming at improving various protein properties like stability, expression, activity, binding affinity, and specificity.
Cradle's technology has shown to double the speed of most projects compared to industry benchmarks, demonstrating its potential to significantly accelerate the design and optimization of proteins
In this engaging episode, I sat down with Elise de Reus, co-founder at Cradle, and we talked about how the field has evolved post-AlphaFold and the role Cradle plays in pushing the boundaries of protein optimization using gen AI.
The discussion also touches upon the inherent challenges of melding AI with biological research, particularly the validation of AI-generated designs in the wet lab. Elise elaborates on Cradle's approach to navigating these obstacles, underscoring the broader implications of their work across industries, from pharma to food sustainability.
A significant part of our conversation revolves around the evolving career landscape in biotech and AI.
Elise passionately speaks about the burgeoning opportunities for information technologies and machine learning professionals within life sciences. She encourages those with a tech background to venture into bioengineering. She highlights the interdisciplinary nature of modern scientific breakthroughs and Cradle's own diverse team as prime examples of the innovation that cross-disciplinary expertise can foster.
Watch the full episode:
The new AI platform beats AlphaFold in predicting protein-ligand structures
San Diego-based Iambic Therapeutics, founded in 2019, has announced its updated NeuralPLexer AI model.
According to this white paper, NeuralPLexer achieved a 75% accuracy rate in predicting protein-ligand structures, edging out the performance of Google DeepMind's AlphaFold, which reported a 74% success rate last October.
Notably, the precision of NeuralPLexer escalates to 93% with the inclusion of extra details on adjacent amino acids.
The company is preparing to reach a major milestone -- launching initial human trials for IAM1363, its pioneering HER2-targeting cancer therapy, this quarter.

Prevention >> Treatment
I came accross this LinkedIn post by Noubar Afeyan, Founder & CEO, Flagship Pioneering, and Co-founder & Chairman, Moderna, and I think it is an important one to know about.
Noubar touches upon The Preventive Health Savings Act (H.R. 766), reintroduced by Representatives Michael Burgess and Diana DeGette.
The Act aims to shift the focus of healthcare from treatment to prevention by changing how the Congressional Budget Office (CBO) evaluates the cost of preventive health policies.
The bill proposes extending the CBO's fiscal impact analysis from 10 to 30 years, thereby highlighting the long-term savings of preventive care and encouraging policymakers to invest in early interventions like preventive drugs and vaccines.
This can be an imporant legislative change with the potential to transform healthcare from a system that reacts to illness to one that proactively preserves health.
AI Already Impacts Drug Development
In a recent video interview with CNBC, Vas Narasimhan, CEO of Novartis, shares his vision about AI in drug discovery. He thinks it won’t impact early stages of drug discovery within the next five years.
However Vas points out that AI has already impacted drug development and clinical research: e.g.: new trial protocols, working with regulators, working with large patients datasets, etc.
He estimates that AI already helps save 6-9 months of drug development, which is obviously a huge financial saving.
9 Innovative Life Sciences Companies to Watch in 2024
The biotech and pharmaceutical industries are entering 2024 amid a wave of innovation and technological advancement.
Below BiopharmaTrend reporter Dana Sokolova highlighted several notable companies that might be interesting to watch this year:
Generate Biomedicines
Generate Biomedicine is a biotechnology company leveraging the power of computational methods to design proteins possessing a desired function that have never existed in nature.
Company’s technology relies on two main elements. The first involves generating new proteins de novo, where a computer designs sequences that can bind to specific targets without prior knowledge of the binding process, surpassing the limitations of the immune system's natural output. The second focuses on optimization, transforming the concept of a computationally designed protein into a practical therapeutic. To achieve this, Generate:Biomedicines employs an optimization suite that refines native proteins into effective therapeutics for specific targets.
Since the company’s launch in 2018 they managed to secure substantial funding for achieving their goals. In their latest Series C funding round in September 2023, Generate:Biomedicines secured $273 million in Series C funding, one of the largest for a biotech firm last year, elevating their total equity financing to nearly $700 million since 2020.
Vial
While the cost of clinical trials in the world is plummeting following Eroom's law, Vial, a San Francisco-based contract research organization (CRO), made its goal to reduce the cost of clinical trials by an order of magnitude.
Vial aims to streamline the clinical trial process through integration of eSource, Electronic Data Capture, and electronic Patient Reported Outcomes into a single system. This platform is designed to be modern, intuitive, and responsive, enhancing the efficiency of trials while ensuring they remain cost-effective for biotech sponsors. The company operates across various therapeutic areas, including dermatology, ophthalmology, oncology, gastroenterology, neurology, cardiology, medical devices, rare diseases, and digital therapeutics.
Currently, Vial is running 12 clinical trials, two of which are in Phase III. Trials the company is involved in range from real-world efficacy study of an eye disease to trials for tropical diseases in partnership with the nonprofit Medicines Development for Global Health. You can learn more about how Vial is operating in this Century of biotech blog post.
Verve Therapeutics
Founded in 2018 in Boston, Verve Therapeutics aims to address the ongoing challenge of cardiovascular disease, which, despite advancements in treatment and care, continues to be the primary cause of death globally.
In the summer 2023 the company presented a novel technique to help prevent heart disease that has been highlighted in Science. This technique involves editing the genetic code within the body to lower levels of "bad" cholesterol, potentially offering a long-term solution for individuals with high cholesterol due to genetic predispositions.
This method involves an infusion of a base editor designed to inactivate a liver protein known as PCSK9 that plays a key role in cholesterol regulation. The clinical trial demonstrated that this approach could efficiently target and edit genes within the liver, marking a shift towards using gene editing technologies for common health issues like high cholesterol. This was the first instance of using a CRISPR-derived base editing tool in humans to treat a disease, suggesting a potential for broader applications beyond rare genetic conditions.
However, the technology's safety and cost implications remain areas of concern. The trial revealed that while the base editor successfully reduced PCSK9 and LDL cholesterol levels in patients, there were instances of serious cardiac events, raising questions about the treatment's safety profile.
Additionally, the high cost of gene therapies could limit access to this treatment. Despite the challenges, Verve Therapeutics plans to expand its trials and aims to make the treatment more accessible than existing gene therapies.
Concerto Biosciences
Concerto Biosciences is pioneering the field of microbial community restoration. Founded in 2020 by a team of innovators from MIT and the Broad Institute, Concerto is developing kChip technology to measure and understand millions of microbial interactions.
The company aims to redefine humanity's relationship with microbes by moving away from traditionally employed microbial eradication towards a model that seeks to understand, preserve, and enhance beneficial microbial ecosystems.
Concerto is collecting data on the complex networks of microbial life to develop "ensembles" - synergistic combinations of microbes aimed at healing damaged microbial communities. With over 6 million microbial interactions measured, the company has established a significant foundation for its research, including a comprehensive human skin microbe biobank.
This technology has already facilitated the creation of their first product, Ensemble No.2 (ENS-002), targeting the skin microbiome to alleviate the symptoms of eczema.
Insilico Medicine
Insilico Medicine is a biotechnology company pioneering the use of generative artificial intelligence (AI) and deep learning for drug discovery and development.
Founded in 2014 by Alex Zhavoronkov, the company aims to leverage AI to accelerate the process of identifying promising drug candidates, predicting their molecular properties, and designing novel molecules for a wide range of diseases.
Insilico has developed several AI-driven platforms, among which are PandaOmics for target identification and Chemistry42 for designing novel drug compounds, and inClinico for modeling clinical trials. The platforms are combined in an end-to-end Pharma.AI engine.
In early 2023, INS018_055, a novel antifibrotic small molecule inhibitor by Insilico, received positive topline data in Phase I yielding consistent results, demonstrating favorable safety, tolerability, and pharmacokinetics (PK) profiles, supporting the initiation of the Phase II study.
The trials aim to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of INS018_055 in patients with Idiopathic Pulmonary Fibrosis (IPF) over a 12-week oral dosage regimen. The case of Insilco highlights the potential of generative AI in drug development for the unmet medical needs.
Quris AI
92% of all clinical trials are poised to fail.
To address this challenge, Quris AI combined the power of artificial intelligence and organ-on-a-chip systems into a unique Bio-AI Clinical Prediction Platform.
This platform integrates high-throughput 3D and multi-organ technologies, real-time sensing, and stem-cell genomic diversity with advanced machine learning to improve the prediction of clinical safety for drug candidates.
Quris AI's technology uses interconnected miniaturized human organs (for example, the liver and brain), to simulate human metabolic responses more accurately than traditional organ-on-a-chip models. This system is capable of generating extensive data on drug metabolites in time-dependent manner through integrated sensors, aiming to enhance the accuracy of safety predictions.
By applying AI to analyze the large datasets generated by its platform, Quris takes a step beyond the capabilities of other organ-on-a-chip technologies allowing for the automated testing of drugs. The platform has demonstrated high sensitivity and specificity in detecting liver toxicity and offers scalability and cost-effectiveness advantages. With 29 granted and pending patents, Quris is positioned to contribute to the shift towards non-animal testing methods in drug development, supported by recent legislative changes like the US FDA’s Modernization Act 2.0.
Lantern Pharma
Dallas-based Lantern Pharma Inc. integrates artificial intelligence (AI) with oncology to enhance the efficiency of clinical trials via biomarker-led clinical trial design.
Since its creation in 2014, the company aims to improve standards of care for cancer patients by expanding therapeutic indications space, identifying combination therapy opportunities, and designing better clinical trials with precision-based patient selection strategies.
To achieve these goals, Lantern developed a ground-breaking tool RADR®, an AI-driven platform that exploits machine learning for identifying mechanisms of action (MoA), driving preclinical development of oncology assets, identifying novel therapeutic indications, and discerning and predicting patient responses to specific drugs. RADR® analyzes over 25 billion clinical data points, more than 154 drug-tumor interactions, and 130,000+ patient records across 17 databases. This end-to-end process transforms multi-omics data into an optimal model that predicts drug responses, generating candidate biomarkers and aiding in patient stratification for clinical trial design.
Lantern's portfolio now includes four drug candidates across two Phase 2 programs, an antibody-drug conjugate program across 12 cancer indications, and several partner programs, illustrating the platform's potential in enhancing clinical therapeutic pipelines in the industry. Through this data-driven method, Lantern has also streamlined their preclinical drug development process, managing to reduce the average time from AI-derived insights to first-in-human clinical trials to 2-3 years at a budget of $1.0-2.0 million per program.
Atomic AI
Founded in May 2021, San Francisco-based Atomic AI is combining the power of machine learning with structural biology to discover novel RNA therapies. Atomic AI’s proprietary AI-driven 3D RNA structure engine, known as PARSE, generates RNA structural datasets, integrating machine learning foundation models with large-scale, in-house experimental wet-lab biology to unveil functional binders to RNA targets. The company’s technology has the ability to predict structured, ligandable RNA motifs at unprecedented speed and accuracy, a key barrier to current approaches to RNA drug discovery.
In December 2023, the company unveiled a novel platform ATOM-1 representing a large language model (LLM) that leverages chemical mapping data to predict the structure and function of RNA. ATOM-1 aims to address challenges associated with designing RNA therapeutics by optimizing key characteristics of RNA modalities (stability, toxicity, and translational efficiency) with a minimal amount of initial data points.
Atomic AI has successfully secured $42 million in funding across two rounds of investment, with the most recent capital infusion coming from a Series A round in January 2023. The company boasts support from 14 investors, including notable recent contributors Nat Friedman and Neal Khosla.
Kymera Therapeutics
Kymera Therapeutics, Inc. was one of the first companies that saw a therapeutic potential in a naturally occurring phenomenon of protein degradation. Today, Kymera is a clinical-stage biopharmaceutical company based in Massachusetts advancing a new class of small molecule medicines using targeted protein degradation (TPD).
This technology addresses the root cause of the disease by selectively eliminating disease-causing proteins via the body's natural cellular recycling system.
Kymera creates heterobifunctional small molecules that redirect natural protein degradation by engaging enzymes called E3 ubiquitin ligases to recruit disease-causing proteins and place a chain of ubiquitin molecules on the recruited protein.
The ubiquitin tag is recognized by the cell’s recycling systems—the proteasome—to selectively break down the protein. These molecules are catalytic, performing this tagging action multiple times within the cell. For hit identification, the company uses such techniques as DNA encoded libraries, fragment and X-ray based screenings, machine learning and artificial intelligence hit-validation, structure and pharmacokinetic/pharmacodynamic-centric enabled lead optimization. Kymera focuses on therapeutic areas that cannot be addressed by traditional approaches, targeting undrugged proteins and broad pathways with strong genetic and clinical validation in a disease-agnostic way.
Read also: Identifying High Impact Tissue Sparing E3 Ligases and Their Binders
Currently the company has 5 drug candidates in the fields of oncology and immunology, 3 of which are in phase I of clinical trials, and 2 in phase II. The most recent achievement of Kymera was FDA fast track designation for KT-333 for treating R/R CTCL and PTCL. KT-333, a STAT3 degrader, targets inflammatory, autoimmune diseases, and various cancers. It also has orphan drug designation for CTCL and PTCL. A Phase I trial is assessing KT-333's safety and efficacy in adults with R/R leukemias, solid tumors, and lymphomas.


